Mikel Tainta
Publications 25
#1Katrina M. Moore (UCL: University College London)H-Index: 1
#2Jennifer M. Nicholas (Lond: University of London)H-Index: 20
Last.Daniel H. GeschwindH-Index: 129
view all 171 authors...
Summary Background Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third of cases being genetic. Most of this genetic component is accounted for by mutations in GRN, MAPT, and C9orf72. In this study, we aimed to complement previous phenotypic studies by doing an international study of age at symptom onset, age at death, and disease duration in individuals with mutations in GRN, MAPT, and C9orf72. Methods In this international, retrospective cohort study, we col...
#1Sarah Westwood (University of Oxford)H-Index: 6
#2Alison L. Baird (University of Oxford)H-Index: 8
Last.Isabelle Bos (UM: Maastricht University)H-Index: 4
view all 50 authors...
#1Liu Shi (University of Oxford)H-Index: 1
#2Liu Shi (University of Oxford)H-Index: 4
Last.Alejo J. Nevado-Holgado (University of Oxford)H-Index: 8
view all 53 authors...
Abstract Introduction Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. Methods 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information F...
#1Daniel Stamate (Lond: University of London)H-Index: 6
#2Min Kim (Steno Diabetes Center)H-Index: 6
Last.Cristina Legido-Quigley (Steno Diabetes Center)
view all 45 authors...
INTRODUCTION: Machine learning (ML) may harbor the potential to capture the metabolic complexity in Alzheimer9s Disease (AD). Here we set out to test the performance of metabolites in blood to categorise AD when compared to CSF biomarkers. METHODS: This study analysed samples from 242 cognitively normal (CN) people and 115 with AD-type dementia utilizing plasma metabolites (n=883). Deep Learning (DL), Extreme Gradient Boosting (XGBoost) and Random Forest (RF) were used to differentiate AD from C...
#1Shengjun Hong (University of Lübeck)H-Index: 1
#2Dmitry Prokopenko (Harvard University)H-Index: 11
Last.Lars Bertram (University of Lübeck)H-Index: 54
view all 46 authors...
Alzheimer9s disease (AD) is the most prevalent neurodegenerative disorder and the most common form of dementia in the elderly. Susceptibility to AD is considerably determined by genetic factors which hitherto were primarily identified using case-control designs. Elucidating the genetic architecture of additional AD-related phenotypic traits, ideally those linked to the underlying disease process, holds great promise in gaining deeper insights into the genetic basis of AD and in developing better...
#1Olivia BelbinH-Index: 19
#2Daniel AlcoleaH-Index: 23
Last.Alberto LleóH-Index: 43
view all 15 authors...
#1Alberto LleóH-Index: 43
#2Daniel AlcoleaH-Index: 23
Last.Kaj Blennow (University of Gothenburg)H-Index: 123
view all 28 authors...
Abstract Introduction Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined. Methods We included 467 subjects from the BIOMARKAPD study with at least two serial CSF samples. Diagnoses were subjective cognitive decline (n = 75), mild cognitive impairment (n = 128), and AD dementia (n = 110), and a group of cognitively unimpaired subjects (n = 154) were also included. We measured baseline and follow-up CSF levels of total tau (t-tau), p...
3 CitationsSource
#1Min Kim ('KCL': King's College London)H-Index: 6
#2Stuart G. Snowden (University of Cambridge)H-Index: 5
Last.Cristina Legido-Quigley ('KCL': King's College London)H-Index: 24
view all 51 authors...
Abstract Introduction A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers. Methods This study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of i...
1 CitationsSource